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Abstract
Purpose of Review—Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) 
emerged as an important source of cells for cardiovascular regeneration. This review summarizes 
protocols for generating hPSC-ECs and provides an overview of the current state of the research in 
clinical application of hPSC-derived ECs.
Recent Findings—Various systems were developed for differentiating hPSCs into the EC 
lineage. Stepwise two-dimensional systems are now well established, in which various growth 
factors, small molecules, and coating materials are used at specific developmental stages. 
Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing 
undefined components from the differentiation system, improving the differentiation efficiency, 
and proving their direct vascular incorporating effects, which contrast with adult stem cells and 
their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators 
improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described 
long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level.
Summary—hPSC-derived ECs can be as a critical source of cells for treating advanced 
cardiovascular diseases. Over the past two decades, substantial improvement has been made in the 
differentiation systems and their clinical compatibility. In the near future, establishment of fully 
defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, 
with some additional pre-clinical studies, will move this therapy into a vital option for treating 
those diseases that cannot be managed by currently available therapies.
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Introduction
Ischemic cardiovascular diseases are the major causes of morbidity and mortality in 
industrialized countries. Despite significant efforts made over the last several decades, 
treating patients with ischemic cardiac and vascular disease remains a challenge [1]. Since 
damage to or loss of blood vessels, of which the main elements are endothelial cells (ECs), 
are the main pathophysiologic feature of these diseases, targeting ECs and growing blood 
vessels from them is a rational step for treating these entities. Specifically, stem cell-derived 
ECs are expected to induce therapeutic neovascularization, proper blood perfusion, and 
tissue repair [2].
Of available approaches, many earlier studies used adult stem or progenitor cells, such as 
endothelial progenitor cells, mesenchymal stem cells, or bone marrow mononuclear cells. 
While animal studies showed very promising outcomes, the overall results of the clinical 
trials were modest at best. Their inability to make durable vessels in vivo and dependence on 
paracrine effects are known to be the major reasons [3–6]. Accordingly, more recent studies 
have attempted using endothelial cells derived from human PSCs (hPSCs), which include 
human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) for 
generating ECs in vivo, promoting revascularization, and inducing ischemic tissue repair [7, 
8••, 9]. However, hurdles remain in their paths toward clinical use. Particularly, the 
development of a clinically compatible system for generating ECs and overcoming low 
survival of transplanted cells in ischemic environments are major concerns. This review will 
focus on progress of differentiation systems of hPSCs toward ECs from a clinical 
perspective, their therapeutic potential in vascular regenerative medicine, and strategies to 
improve survival of the implanted cells.
Differentiation of hPSCs into Endothelial Lineages
Two approaches have been widely known for differentiating hPSCs to ECs: three 
dimensional (3D) embryoid body (EB)-mediated differentiation and two-dimensional (2D) 
monolayer-directed differentiation (Table 1). In the EB-mediated system, the first step is to 
let hPSCs spontaneously form EBs in suspension culture without LIF and FGF2 [10]. These 
EBs are composed of three germ layers and usually after 2 weeks of culture, cells expressing 
EC markers and vascular-like structures are observed. In EB-mediated differentiation, since 
cells are permitted to spontaneously differentiate into multiple lineage cells, the percentage 
of ECs is low even though various angiogenic factors are used for differentiation (1 to 14%) 
[11–17]. The 2D culture system, which was developed later to improve differentiation 
efficiency and consistency, uses a monolayer cell culture of hPSCs with either mouse feeder 
cells [18, 19] or coating material [8••, 9, 20, 21•, 22, 23]. These systems allow homogeneous 
exposure of cells to the medium and yield higher and more consistent differentiation 
efficiency. In the 2D system, coating with extracellular matrix proteins such as Matrigel [9], 
or collagen [8••] gradually replaced the feeders due to concerns of animal product 
contamination and difficulties in target cell purification.
The main reason that 2D systems result in higher and consistent efficiency in EC generation 
is the use of stepwise differentiation methods. By following the embryonic developmental 
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scheme toward endothelial cells, the differentiation steps are organized into distinct stages 
and each differentiation step is controlled by using growth factors, cytokines, and small 
molecules that direct different developmental stages. First, hPSCs are differentiated into 
mesodermal lineages. Combinations of BMP4, selective small molecule inhibitor GSK-3β, 
and FGF2 are generally used [7, 8••, 9, 13, 21•, 24]. Markers of mesodermal cells (e.g., T, 
MIXL, EOMES, or KDR) are commonly used to assess differentiation efficiency. Next, 
these mesodermal cells are further differentiated into endothelial and vascular progenitor 
cells. Various growth factors and small molecules are used at this stage. For example, 
mesodermal-stage cells such as KDR-positive cells are differentiated into EC lineages by 
BMP4, activin-A, FGF2, and VEGFA [22]. In this study, KDR-expressing cells are further 
differentiated into more mature PECAM1/CDH5 double-positive ECs [22]. Since the 
efficiency of these protocols is not high, further refinement was attempted by other groups. 
Studies demonstrated that in combinations with VEGFA, a small molecular inhibitor of 
TGF-β (SB431542) or forskolin showed higher expression of CDH5 (VE-Cadherin) in 
hPSC-ECs [21•, 25]. Even higher expression of CDH5 was achieved when CHIR99021 was 
combined with DLL4 with a lower concentration of VEGFA (10 ng/ml) [8••]. DLL4, a 
Notch ligand, has been shown to enhance the efficiency of EC differentiation while 
inhibiting hematopoietic-lineage differentiation. Usually the final stage is to select EC 
lineage cells via EC-specific surface markers. KDR and CD34 are selective for progenitor 
level ECs [9, 22] and PECAM1 [15, 24, 25], CDH5 [8••, 11, 19, 21•], and VWF [7] are used 
for isolating more mature ECs. In another study, KDR-expressing mesodermal progenitors 
were differentiated into both ECs and mural cells by VEGF and PDGF-BB [21] While 
PECAM1 was classically used for purifying ECs, hPSC-derived ECs selected by CDH5 
showed excellent EC features [8••, 11, 21•]. CDH5-positive cells express other important 
EC-specific proteins including PECAM1, KDR, VWF, CD34, CD105, and ANGPT-2 [8••, 
11, 21•]. CDH5-expressing hPSC-ECs isolated by magnetic-associated cell sorting (MACS) 
demonstrated high purity (> 95%) and robust EC characteristics [21•]. Our recent study also 
demonstrated that CDH5-positive hPSC-ECs are highly enriched in EC proteins: VWF 
(98.6%), TEK (79.0%), and KDR (66.3%) [8••].
Furthermore, arterial, venous, and lymphatic vascular specification was demonstrated in 
hPSC-ECs. In certain EC differentiation conditions, lymphatic EC markers such as PDPN 
and LYVE1 were expressed, suggesting lymphatic lineage differentiation [24]. One study 
showed differentiation into arterial ECs characterized by Ephrin B2 and Notch1 with a 
higher concentration of VEGFA, and venous ECs characterized by EphB4 and CoupTFII 
expression with a lower concentration of VEGFA [24]. In another study, lymphatic ECs 
were specifically isolated from hPSCs via endothelial differentiation and double-sorting with 
PDPN and LYVE1 and were shown to improve wound healing by augmenting lymphatic 
neovascularization [26]. While few studies demonstrated maintenance of EC markers over 
long-term culture [12, 13], it is usually accepted that an EC phenotype is not well 
maintained after 2 weeks in culture [16].
Characterization of hPSC-Derived ECs
Four general hallmarks that define ECs are used to prove the identity of hPSC-derived ECs 
as ECs. These are presence of cobblestone-like morphology, expression of EC-specific 
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markers at the mRNA and protein levels, in vitro cell biological characteristics of ECs, and 
EC generation in vivo. ECs differentiated from hPSCs express EC-specific markers such as 
KDR, TEK/TIE2, CDH5, PECAM1, VWF, and NOS3 at both mRNA and protein levels and 
show typical cobblestone-like morphology. Immunostaining demonstrates localization of 
CDH5 and PECAM1 at the plasma membrane, expression of VWF with a typical punctate 
pattern, and localization of ANGPT-2 in Weibel-Palade bodies [8••, 11, 21•]. Flow 
cytometric analysis for PECAM1 or CDH5 further confirms their identity as ECs and 
provides the efficiency of EC generation. More recently, genome-wide transcriptome 
analysis and metabolic profiling has demonstrated the identity of hPSC-ECs in a more 
sophisticated manner. In terms of the developmental closeness between hPSC-ECs and adult 
ECs, studies showed controversial results. While a few studies showed similarity between 
hPSC-ECs to primary ECs such as HUVECs and human coronary artery endothelial cells 
[21•], most suggested that hPSC-ECs are less mature than adult ECs. In cell biological 
assays, hPSC-ECs show specific functional characteristics such as endothelial specific 
endocytosis and trafficking events. The endocytic capability of hPSC-ECs can be tested by 
their uptake of acetylated LDL with a punctated pattern [7, 8••, 9, 11, 15, 20, 21•]. P-selectin 
translocates onto the hPSC-EC surface upon histamine treatment [11]. Nitric oxide (NO) 
production, a most authentic index representing functional competence of hPSC-ECs, was 
also demonstrated in a recent study [8••]. Moreover, hPSC-derived ECs formed a tube-like 
structure within Matrigel gel [8••, 9, 15, 16, 22] or collagen gel [17, 20]. While not a 
required element for confirming hPSC-ECs, pro-angiogenic potential of hPSC-ECs 
measured by expression of angiogenic factors and their promotion of tube-formation by 
HUVECs on Matrigel are frequently demonstrated [8••, 11, 21•]. Finally, EC generation in 
vivo is the final step to prove the genuine identity and function of hPSC-ECs. For in vivo 
animal models, hindlimb ischemia models are mostly commonly used because these models 
can provide therapeutic outcomes at the same, but other models such as skin wound [27] or 
corneal pocket models are also used to prove in vivo vasculogenic potential [28, 29]. 
However, not all studies and even animal studies conducted in vivo lacked confocal imaging 
studies to confirm the exact co-localization of transplanted hPSC-ECs with EC markers and 
demonstrate their incorporation into the native vasculature. While most of the in vivo studies 
demonstrated short-term in vivo vasculogenic activities of hPSC-derived ECs, Wang et al. 
and Lee et al. showed that in vivo transplanted hPSC-derived ECs, when they were delivered 
with biomaterials, survived and contributed to vessel formation for 5 and 10 months, 
respectively, suggesting their long-term survival and vasculogenic effects [8••, 20] (Table 1).
Considerations in the Use of hPSC-Derived ECs in Vascular Regenerative 
Medicine
Studies using hPSC-ECs as a therapeutic agent demonstrated favorable effects for enhancing 
recovery from ischemia and promoting tissue regeneration [7, 8••, 9]. These results 
collectively indicate potential therapeutic utility of hPSC-ECs for cardiovascular tissue 
regeneration. Due to virtually unlimited proliferative capacity, hPSCs have huge advantages 
as a therapeutic agent for treating cardiovascular disease.
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First, hPSCs must be differentiated in conditions that are fully defined and free of 
xenogeneic components. For example, hPSC-derived ECs generated in presence of animal 
serum and/ or animal-derived feeder cells will not be compatible for human therapeutic 
applications due to regulatory issues and graft rejection from exposure to animal-derived 
pathogens. In recent studies, fully defined differentiation systems that can differentiate 
hPSCs into ECs were reported [8••, 21•, 25]. Second, the culture system should generate 
hPSC-ECs with high efficiency and be clinically scalable to lower the costs. Most recently 
developed systems demonstrated a pre-sorting efficiency between 20 and 40% [8••, 9, 21•, 
25] and showed scalability due to the use of 2-D system and defined components. Third, the 
differentiation protocols should yield similar differentiation efficiency across multiple cell 
lines [8••, 22]. This is particularly important when considering autologous cell therapy using 
hiPSC-ECs. Fourth, the ECs derived from hPSCs should be purified at the final stage of EC 
differentiation from hPSCs to avoid potential side effects caused by the presence of other 
types of cells. Fifth, vessel-forming or vasculogenic capability must be verified in vivo [7, 
8••, 9, 15–17, 21•, 22, 24, 25]. Sixth, therapeutic effects should be confirmed in animal 
models of ischemic cardiovascular disease [7, 8••, 9]. Seventh, a major risk for therapeutic 
use of hPSCs is teratoma formation following transplantation [30, 31]. Thus, the 
tumorigenic potential or adverse effects of implanted cells must be ruled out by long-term 
follow-up. So far, only one study met all the above criteria and has demonstrated 
contribution of hPSC-ECs to new vessel formation in vivo [8••].
Use of Biomaterials to Improve Cell Survival In Vivo
A major issue to maximize the clinical utility of hPSC-ECs is their capability for long-term 
survival. It is well known that regardless of the cell type, low cell survival limits the 
therapeutic effects of any cell therapy in the cardiovascular field. No or few studies using 
bare cell transplantation demonstrated meaningful cell survival over more than several 
months even for hPSC-derived cells. When adult stem cells were injected into ischemic 
hearts, > 50% of the injected cells disappeared immediately, and virtually, all cells were lost 
within a month [18, 32]. The survival rate of hESC-derived ECs injected into infarcted 
hearts was shown to be less than 10% at 1 week, and less than 1% at 8 weeks [33]. Similarly, 
hPSC-derived cardiomyocytes showed poor survival in ischemic hearts, usually disappearing 
within a month [34]. Even when cells were injected in a hindlimb ischemia model, the 
results were not much different. Bioluminescent imaging (BLI) demonstrated that 
mesenchymal stem cells (MSCs) which were transplanted into ischemic hindlimbs 
disappeared by day 6 [35] or 20 [36]. Similarly, hPSC-derived ECs showed no detectable 
bioluminescence signals after 14 days in a hindlimb ischemia model [37]. Intriguingly, our 
study demonstrated relatively longer (> 3 months) survival of hPSC-ECs when these cells 
were injected into a hindlimb ischemia model by microscopic examination, although the 
degree of survival was not robust [8••].
This short-term survival not only limits the therapeutic effects, but also prevents 
investigation of the cell behavior of hPSC-derived ECs and their genuine capability for 
vessel formation in ischemic tissues. To overcome low cell survival in vivo, biomaterial-
based strategies have been attempted in cardiac models with other cell types [8••, 38–42]. 
Likewise, endeavors were made for efficient cell delivery and longer-term engraftment to 
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improve therapeutic effects of hPSC-derived ECs and to determine the in vivo behavior of 
the transplanted hPSC-ECs [20]. Wang et al. demonstrated that the hESC-derived ECs which 
were co-implanted with 10T1/2, a mouse mesenchymal precursor cell line in a fibronectin-
collagen gel, into cranial windows in severe combined immunodeficient (SCID) mice, 
contributed to blood vessel formation, integrating into their host circulatory system, and 
served as blood conduits for 151 days after transplantation [20]. Only two studies are found 
using hPSC-ECs alone with biomaterials in ischemic animal models. Mulyasasmita et al. 
demonstrated that in a hindlimb ischemia model, inflammation was reduced and muscle 
regeneration was promoted by co-delivery of growth factors and hiPSC-derived ECs using 
injectable MITCH-PEG hydrogels [43]. Lee et al. recently demonstrated that biomaterial-
mediated delivery of hPSC-derived ECs could prolong cell survival and improve therapeutic 
neo-vascularization [8••]. They selected a novel injectable self-assembled peptide 
amphiphile (PA) nanomatrix gel [41, 44, 45], and generated PA-RGDS by incorporating cell 
adhesive ligand Arg-Gly-Asp-Ser (RGDS) and a matrix metalloprotease-2 (MMP-2) 
degradable sequence into the PA. RGDS, a fibronectin-derived cell adhesive ligand, 
promotes cell adhesion and the MMP-2 degradable sequences permit cell-mediated 
degradation of the nanomatrix gel and migration of encapsulated cells from the gel into the 
host tissues. In this study, they demonstrated that hPSC-derived ECs survived for more than 
10 months in ischemic tissues, incorporated into the host vessels continuously and 
dynamically over this period following the remodeling of the vessels, contributed to new 
vessel formation, and showed better vascular regenerative capacity compared to the bare 
hPSC-EC injected group.
Summary and Future Perspective
We believe hPSC-ECs will be an important source of cells for ischemic cardiovascular 
diseases therapy. However, several hurdles remain. Since each of the many studies used its 
own protocols and cell types, more studies are needed to determine the phenotypic and 
functional differences between the different types of hPSC-ECs. Also, the successive 
culturability of established hPSC-ECs was not convincingly demonstrated. This is important 
because numerous cells are required for clinical therapy even when an autologous approach 
is employed. While this problem can be somehow addressed by using a large number of 
hPSCs for differentiation, establishing a protocol for passaging hPSC-ECs while 
maintaining the phenotype is important biologically as well. In addition, the genomic 
stability of differentiated hPSC-ECs has not been addressed. Long-term in vivo safety needs 
to be demonstrated using multiple different hPSC lines. Finally, optimization of biomaterial-
mediated cell delivery and tissue engineering with hPSC-ECs will be an important future 
step in the use of hPSC-ECs.
Other biologically important questions await further studies. The developmental stages or 
maturity of hPSC-ECs developed by different protocols need to be addressed together with 
their biological potency. Generation of specific EC type, particularly arterial versus venous 
ECs, and their phenotypic maintenance has been virtually uninvestigated. Many therapeutic 
studies still show discrepancies between the degree of functional recovery and the direct 
vessel-forming effects of hPSC-ECs. Thus, the paracrine effects versus direct vessel-forming 
effects of various types of hPSC-ECs need to be explored. While there is advancement in the 
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therapeutic utility of hPSC-ECs, other important applications of stem cells such as disease 
modeling and drug testing are relatively behind compared to other stem cell-derived cells 
such as hPSC-derived cardiomyocytes.
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